A year-to-date sales report for the radiopharmaceutical company Advanced Accelerator Applications (AAA) indicates that the company experienced 28.9 percent growth in sales, equaling about $68.7 million in the first nine months of 2014. Net income for the first three quarters of the year was gauged at approximately $1.5 million.

Targeting oncogene-driven activation of DNA damage could be an effective way to tap into the earliest stages of cancer development, or tumorigenesis. An investigative molecular imaging agent was able to do just that in a preclinical Oxford University study published ahead of print Nov. 13 in the Journal of Nuclear Medicine.

Navidea Biopharmaceuticals announced today that technetium-99m tilmanocept (Lymphoseek) has been approved by the European Commission for the detection of sentinel lymph node involvement in primary breast cancer, melanoma and localized squamous cell carcinoma.

When four-state Mercy broke ground on a four-story, 120,000-square-foot virtual-care center on a patch of green in Chesterfield, Mo., last spring, the blueprint represented a bold and visionary step into American healthcare’s digital future, as the center may be the first of its kind anywhere in the world. The organization estimates that the center will manage more than three million telehealth visits in the first five years following its scheduled 2015 opening.

Protea Biosciences, a biomedical company based in Morgantown, W. Va, announced yesterday that third quarter financial results amounted to $517,569, the highest revenue on record for the company. However net losses are still steep at more than $4.6 million for the third quarter.

Even mild cases of dental disease could have long-term effects on amyloid plaque development and brain health, according to a neuroimaging study published online Nov. 5 in Neurobiology of Aging.

Two novel technetium-99m agents, when used with SPECT or planar imaging, have been found to effectively target prostate specific membrane antigen (PSMA) in advanced prostate cancer within bone, lymph nodes and soft tissues, according to a study published in the November issue of the Journal of Nuclear Medicine.

Infections related to heart valve prosthesis are usually diagnosed with echocardiography, but it can miss key areas of infection. It is here that FDG PET or leukocute scintigraphy can step in, but a recent comparison study of the two nuclear medicine procedures published Nov. 13 in the Journal of Nuclear Medicine shows that FDG PET may be the best option.